Drug Trial Radar · NCT04076371
The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia
Last checked: Nov 19, 2026Latest source record: Sep 3, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,640
Actual
Start
Jan 2012
Primary completion
Dec 2018
Study completion Dec 2018
Sponsor
- Lead sponsor
- Beijing HuiLongGuan HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 3, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized, double-blind trial of the treatment effect of dose-low antipsychotics combined with low-dose sertraline in 1640 schizophrenia patients
Conditions
- Schizophrenia
Interventions
olanzapine-sertraline combinationDrug
the patient was prescribed low-dose olanzapine (7.5-10mg/day) combined with low-dose sertraline (50-100mg/day)
only olanzapineDrug
the patient was prescribed moderate to severity dose of olanzapine (12.5-20mg/day)
risperidone-sertraline combinationDrug
the patient was prescribed low-dose risperidone (2-3.5mg/day) combined with low-dose sertraline (50-100mg/day)
only risperidoneDrug
the patient was prescribed moderate to severity dose of risperidone (4-6mg/day)
paliperidone-sertraline combinationDrug
the patient was prescribed low-dose paliperidone (3-4.5mg/day) combined with low-dose sertraline (50-100mg/day)
only paliperidoneDrug
the patient was prescribed moderate to severity dose of paliperidone (6-9mg/day)
ziprasidone-sertraline combinationDrug
the patient was prescribed low-dose ziprasidone (60-100mg/day) combined with low-dose sertraline (50-100mg/day)
only ziprasidoneDrug
the patient was prescribed moderate to severity dose of ziprasidone (120-160mg/day)
Primary outcomes
What the sponsor says the trial is designed to measure.
- changes in psychopathology symptoms on PANSS during antipsychiatric treatmentTime frame: baseline, week 4, week 8, week 12, and week 24
- changes in depressive symptoms on HAMD during antipsychiatric treatmentTime frame: baseline, week 4, week 8, week 12, and week 24
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.